Servier buys into MacroGenics' Phase I anticancer MAb
This article was originally published in Scrip
Executive Summary
Servier is to pay an initial $20 million to Rockville, Maryland-based privately held biotech firm MacroGenics to access the latter's MGA271, an Fc-optimised therapeutic monoclonal antibody that targets the immune regulator B7-H3 and is in Phase I trials to treat solid tumours.